Small Molecule Targeted Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
Small molecule targeted cancer therapies are drugs designed to block the growth of cancerous cells. Conventional cytotoxic medications and chemotherapies usually destroys rapidly dividing cancer cells by inhibiting cell division process. However, small molecule targeted therapies destroys cancerous cells with fewer side effects and high precision. Small molecule targeted cancer therapies can be used for the treatment of various cancers such as prostate cancer, multiple myeloma, breast cancer, lymphoma, melanoma and other cancers.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/small-molecule-targeted-cancer-therapy-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Targeted cancer drugs are broadly classified as follows:
Small Molecules
Monoclonal Antibodies
Small Molecule Drug conjugates
Small molecules can further be classified as follows:
Small molecule proteasome inhibitor (e.g. Bortezomib)
Small molecule cyclin-dependent kinase inhibitor (e.g. Seliciclib)
Small molecule tyrosine kinase inhibitor (e.g. Imatinib)
Geographically, North America is the leading market due to the rise incancer cases. According to the International Agency for Research on Cancer (IARC), around 13 million new cancer cases has been diagnosed worldwide. Moreover, according to the World Cancer Report, incidence rate of cancer could further rise by 50% to 15 million new cancer cases by 2020. Furthermore, the European and Asian-Pacific regions are expected to witness increased market traction due to commercialization of target oriented economic drugs.
The major factors driving this market are rise in incidence rate of cancer, minimal adverse effects, targeted approach and high adoption rate. Additionally, more number of blockbuster drugs such as Novartis’s Glivec are...